Inadequate response or intolerability to oral methotrexate: Is it optimal to switch to subcutaneous methotrexate prior to considering therapy with biologics?

Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration

(2014) Michael H Schiff et al.   ANNALS OF THE RHEUMATIC DISEASES

Methotrexate revisited: considerations for subcutaneous administration in RA

(2014) Randy Jay   CLINICAL RHEUMATOLOGY

Methotrexate: an old new drug in autoimmune disease

(2014) Paola Cipriani et al.   Expert Review of Clinical Immunology

Cost-minimisation analysis of subcutaneous methotrexate versus biologic therapy for the treatment of patients with rheumatoid arthritis who have had an insufficient response or intolerance to oral methotrexate

(2013) Ray Fitzpatrick et al.   CLINICAL RHEUMATOLOGY

Regulation of Inflammation by Adenosine

(2013) György Haskó et al.   Frontiers in Immunology

2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

(2012) Jasvinder A. Singh et al.   ARTHRITIS CARE & RESEARCH

Preference, satisfaction and usability of subcutaneously administered methotrexate for rheumatoid arthritis or psoriatic arthritis: results of a postmarketing surveillance study with a high-concentration formulation

(2011) Frank Striesow et al.   Therapeutic Advances in Musculoskeletal Disease

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

(2010) J. S. Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA

(2010) J. L. Nam et al.   ANNALS OF THE RHEUMATIC DISEASES

Subcutaneous methotrexate is well tolerated and superior to oral methotrexate in the treatment of rheumatoid arthritis

(2010) Beena HAMEED et al.   International Journal of Rheumatic Diseases